GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market ...

Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly ...

We were particularly pleased to see the momentum now being established in our oncology business, and I'm delighted that we filed Blenrep in Europe, Japan, and the U.S. in the quarter. We also ...

Blenrep, a treatment for cancer, and asthma medicine Depemokimab are among the planned new launches. Nonetheless, shares in ...

Q3 2024 Earnings Call Transcript October 30, 2024 GSK plc beats earnings expectations. Reported EPS is $1.29, expectations were $1.23. Operator: Hello, everyone. Welcome to today’s call and webcast.

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...

Blenrep, a treatment for cancer, and asthma medicine Depemokimab are among the planned new launches. Nonetheless, shares in the company fell after it cut its outlook for its annual vaccines sales ...

Blenrep, Depemokimab, Nucala for COPD, Gepotidacin, and our new vaccine to prevent meningitis (MenABCWY).' Sheena Berry, an analyst at Quilter Cheviot, said: 'GSK’s third quarter results for ...